leisure time -WSS

leisure time

author：leisure time 2025-09-02 22:24:32 - browse：88

WASHINGTON — A veteran senator and champion of the biotech sector beat back an unusually strong challenge Tuesday night — thanks in large part to loyal support from the industry.

North Carolina Senator Richard Burr, a Republican who has long protected the bioscience companies that drive his state’s economy, overcame a surprisingly robust challenge from Democratic candidate Deborah K. Ross.

Burr, now finishing his second term in the Senate, serves on committees with oversight of both the Food and Drug Administration and Medicare and Medicaid. He is also chairman of the Select Committee on Intelligence.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies
Next article： ALS advocates say criticism of new drugs misses bigger picture

WSS

Biotech execs pursue obesity drug boom: ‘It’s the early innings’

The Karikó problem: Lessons for funding basic research

Stem cell treatment guidelines are released by FDA

How generative AI is inspiring dreams of a health data revolution

Congress extends some pandemic preparedness programs

The (many) problems with a new study criticizing cancer screening

entertainment

leisure time

hotspot

How one medical school became remarkably diverse

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

FDA approval of Sarepta Duchenne genetic therapy gives me hope

The United States is paying nearly triple for new Covid vaccines

State Dept. review finds Biden bears some blame for Afghanistan failures

'Make People Better': The CRISPR babies story you probably don't know

Trump demands the U.S. pay no more for drugs than other countries … again

Health insurers' Q3 question: how much care are people getting?

Heart attack and stroke risk calculators need revising

Covid hospitalizations on the rise, Humana says

leisure time

Why Novartis is changing the name of its research labs

2023 Nobel Prize in Medicine goes to Karikó and Weissman

Health insurers' Q3 question: how much care are people getting?

What will Novo Nordisk's VC do with its influx of cash?

Trump surgeon general acknowledges mistakes during Covid

How generative AI is inspiring dreams of a health data revolution

knowledge

explore

leisure time

hotspot